Tunitas raises $10M for asthma R&D; bluebird signs off on a big new lease; DeuteRx raises seed money;

@FierceBiotech: Fierce's coverage of the Martin Shkreli saga. More | Follow @FierceBiotech

@JohnCFierce: Ladies and gentlemen, the 2015 Fierce 15. Special report | Follow @JohnCFierce

@DamianFierce: Here's what it's like to try to get Sovaldi in my home town. More from The Atlantic | Follow @DamianFierce

> San Francisco-based Tunitas Therapeutics raised $10 million in Series A cash. The financing was co-led by Ally Bridge Group and WuXi Ventures with the participation of RA Capital Advisors. Tunitas has a new asthma drug in the clinic. Release

> Cambridge, MA-based bluebird has signed up for a 10-year lease at 60 Binney Street, taking 253,000 square feet of space at the building, which is under construction. Bluebird is one of the leaders in a new wave of gene therapy companies.Story

> Andover, MA-based DeuteRx landed $2.8 million in seed financing for a new drug to treat adrenoleukodystrophy (ALD). Release

> Natalie Holles has joined Audentes as senior vice president and chief operating officer, Thomas Soloway has joined as senior vice president and chief financial officer and Kevin Baker, Ph.D., has joined as senior vice president of preclinical development. Release

Medical Device News

@FierceMedDev: Illumina launches solid tumor sequencing panel aimed at Big Pharma researchers. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: MedImmune licenses 3M compound in hopes of developing intratumorally injected cancer drug. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: OraSure reels in $7.2M from HHS for rapid Ebola test. FierceDiagnostics story | Follow @EmilyWFierce

> Baxter makes nice with activist investor Third Point, offers board seats. Report

> Bard to buy out Medicon, its long-standing Japanese JV with Kobayashi. Article

Pharma News

@FiercePharma: Another reason Tresiba uptake is crucial to Novo: Xultophy's blockbuster hopes. FiercePharmaMarketing story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Bayer eyes challenge to oral MS meds with new Betaseron injector. Article | Follow @CarlyHFierce

> New Hampshire AG launches investigation into opioid marketing. Report

> How can Pradaxa, Xarelto and Eliquis finally unseat warfarin? Safety data, analyst says. More

Biotech Research News

> The contentious gene editing field gets a tech upgrade. What now? Story

> FDA's 'breakthrough' endorsement carries real weight with the public. Report

> Looking for an alternative to pricey Daraprim? You may be in luck. More

> Researchers zero in on immune system's role in Alzheimer's. Story

> A molecule isolated from the depths of the ocean shows promise in treating AML. Article

Diagnostics News

> Diagnostics companies strike back at CMS lab test rule. More

> OraSure reels in $7.2M from HHS for rapid Ebola test. Item

> Dako to develop companion diagnostic for Pfizer and Merck KGaA's joint cancer candidate. Report

> Illumina launches solid tumor sequencing panel aimed at Big Pharma researchers. Story

> Quest launches patient analytics tool for healthcare providers. Article

Pharma Marketing News

> Roche poised for MS coup with success in hard-to-treat progressive form. Article

> Looking for the next wave of pharma innovation? Try opening the door to more partners, Accenture says. More

> Another reason Tresiba uptake is crucial to Novo: Xultophy's blockbuster hopes. Story

> New Hampshire AG puts pain drug marketing under his microscope. Item

> JAMA: 'Breakthrough' talk in FDA press releases could unfairly sway consumers. Report

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i